Immunohistological expression of HIF-1α, GLUT-1, Bcl-2 and Ki-67 in consecutive biopsies during chemoradiotherapy in patients with rectal cancer

APMIS

Volumn 121, Issue 2, 2013, Pages 127-138

  Havelund, Birgitte Mayland ^a,b   Sørensen, Flemming Brandt ^a,b   Pløen, John ^a   Lindebjerg, Jan ^a   Spindler, Karen Lise Garm ^a,b   Jakobsen, Anders ^a,b  

^a LILLEBAELT HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Bcl 2; Chemoradiotherapy; Glucose transporter type 1; Hypoxia inducible factor 1 alpha; Ki 67; Rectal neoplasm

Indexed keywords

GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; LEVOLEUCOVORIN; PROTEIN BCL 2; UFT;

ADULT; AGED; ARTICLE; CANCER PATIENT; CHEMORADIOTHERAPY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM BIOPSY; RECTUM CARCINOMA; TUMOR BIOPSY;

ADULT; AGED; BCL-2-ASSOCIATED X PROTEIN; BIOPSY; CHEMORADIOTHERAPY; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KI-67 ANTIGEN; MALE; MIDDLE AGED; RECTAL NEOPLASMS; SPECIMEN HANDLING; TUMOR MARKERS, BIOLOGICAL;

EID: 84872657999     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2012.02949.x     Document Type: Article

References (38)

1. Fleming FJ, Pahlman L, Monson JR. Neoadjuvant therapy in rectal cancer. Dis Colon Rectum 2011;54:901-12.
2. Habr-Gama A, Perez RO, Nadalin W, Nahas SC, Ribeiro U. Jr., Silva e Sousa AH. Jr., et al. Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival. J Gastrointest Surg 2005;9:90-9.
3. Kuremsky JG, Tepper JE, McLeod HL. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 2009;74:673-88.
4. Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, Richter E, et al. The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 2003;22:3213-20.
5. Moeller BJ, Dewhirst MW. HIF-1 and tumour radiosensitivity. Br J Cancer 2006;95:1-5.
6. Vordermark D, Brown JM. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance? Strahlenther Onkol 2003;179:801-11.
7. Airley RE, Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 2007;53:233-56.
8. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
9. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-76.
10. Brown JM, Wilson G. Apoptosis genes and resistance to cancer therapy: what does the experimental and clinical data tell us? Cancer Biol Ther 2003;2:477-90.
11. Brophy S, Sheehan KM, McNamara DA, Deasy J, Bouchier-Hayes DJ, Kay EW. GLUT-1 expression and response to chemoradiotherapy in rectal cancer. Int J Cancer 2009;125:2778-82.
12. Havelund BM, Sorensen FB, Lindebjerg J, Spindler KL, Jakobsen A. Pretreatment HIF-1alpha and GLUT-1 expressions do not correlate with outcome after preoperative chemoradiotherapy in rectal cancer. Anticancer Res 2011;31:1559-65.
13. Korkeila E, Jaakkola PM, Syrjanen K, Sundstrom J, Pyrhonen S. Preoperative radiotherapy downregulates the nuclear expression of hypoxia-inducible factor-1alpha in rectal cancer. Scand J Gastroenterol 2010;45:340-48.
14. Korkeila E, Jaakkola PM, Syrjanen K, Pyrhonen S, Sundstrom J. Pronounced tumour regression after radiotherapy is associated with negative/weak glucose transporter-1 expression in rectal cancer. Anticancer Res 2011;31:311-5.
15. Ban HS, Uto Y, Nakamura H. Hypoxia-inducible factor inhibitors: a survey of recent patented compounds (2004 - 2010). Expert Opin Ther Pat 2011;21:131-46.
16. Schwartz DL, Powis G, Thitai-Kumar A, He Y, Bankson J, Williams R, et al. The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther 2009;8:947-58.
17. Meyn RE, Milas L, Ang KK. The role of apoptosis in radiation oncology. Int J Radiat Biol 2009;85:107-15.
18. Loriot Y, Mordant P, Brown BD, Bourhis J, Soria JC, Deutsch E. Inhibition of BCL-2 in small cell lung cancer cell lines with oblimersen, an antisense BCL-2 oligodeoxynucleotide (ODN): in vitro and in vivo enhancement of radiation response. Anticancer Res 2010;30:3869-78.
19. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994;73:2680-6.
20. Lindebjerg J, Hansborg N, Ploen J, Rafaelsen S, Jorgensen JC, Jakobsen A. Factors influencing reproducibility of tumour regression grading after high-dose chemoradiation of locally advanced rectal cancer. Histopathology 2011;59:18-21.
21. Fokas E, Hanze J, Kamlah F, Eul BG, Lang N, Keil B, et al. Irradiation-dependent effects on tumor perfusion and endogenous and exogenous hypoxia markers in an A549 xenograft model. Int J Radiat Oncol Biol Phys 2010;77:1500-8.
22. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008;8:425-37.
23. Roels S, Slagmolen P, Nuyts J, Lee JA, Loeckx D, Maes F, et al. Biological image-guided radiotherapy in rectal cancer: is there a role for FMISO or FLT, next to FDG? Acta Oncol 2008;47:1237-48.
24. Koh WJ, Bergman KS, Rasey JS, Peterson LM, Evans ML, Graham MM, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 1995;33:391-8.
25. Eschmann SM, Paulsen F, Bedeshem C, Machulla HJ, Hehr T, Bamberg M, et al. Hypoxia-imaging with (18)F-Misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer. Radiother Oncol 2007;83:406-10.
26. Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of trans-tasman radiation oncology group study 98.02. J Clin Oncol 2006;24:2098-104.
27. Lee N, Nehmeh S, Schoder H, Fury M, Chan K, Ling CC, et al. Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009;75:101-8.
28. O'Neil BH, Funkhouser WK, Calvo BF, Meyers MO, Kim HJ, Goldberg RM, et al. Nuclear factor kappa-light chain-enhancer of activated B cells is activated by radiotherapy and is prognostic for overall survival in patients with rectal cancer treated with preoperative fluorouracil-based chemoradiotheraphy. Int J Radiat Oncol Biol Phys 2011;80:705-11.
29. Stift A, Prager G, Selzer E, Widder J, Kandioler D, Friedl J, et al. The early response of p53-dependent proteins during radiotherapy in human rectal carcinoma and in adjacent normal tissue. Int J Oncol 2003;23:1269-75.
30. Lin LC, Lee HH, Hwang WS, Li CF, Huang CT, Que J, et al. P53 and p27 as predictors of clinical outcome for rectal-cancer patients receiving neoadjuvant therapy. Surg Oncol 2006;15:211-6.
31. Tannapfel A, Nusslein S, Fietkau R, Katalinic A, Kockerling F, Wittekind C. Apoptosis, proliferation, bax, bcl-2 and p53 status prior to and after preoperative radiochemotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 1998;41:585-91.
32. Palazzo JP, Kafka NJ, Grasso L, Chakrani F, Hanau C, Cuesta KH, et al. The role of p53, p21WAF1/C1PI, and bcl-2 in radioresistant colorectal carcinoma. Hum Pathol 1997;28:1189-95.
33. Willett CG, Warland G, Hagan MP, Daly WJ, Coen J, Shellito PC, et al. Tumor proliferation in rectal cancer following preoperative irradiation. J Clin Oncol 1995;13:1417-24.
34. Rau B, Sturm I, Lage H, Berger S, Schneider U, Hauptmann S, et al. Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol 2003;21:3391-401.
35. Willett CG, Hagan M, Daley W, Warland G, Shellito PC, Compton CC. Changes in tumor proliferation of rectal cancer induced by preoperative 5-fluorouracil and irradiation. Dis Colon Rectum 1998;41:62-7.
36. Debucquoy A, Goethals L, Geboes K, Roels S, Mc Bride WH, Haustermans K. Molecular responses of rectal cancer to preoperative chemoradiation. Radiother Oncol 2006;80:172-7.
37. Haboubi NY, Schofield PF, Rowland PL. The light and electron microscopic features of early and late phase radiation-induced proctitis. Am J Gastroenterol 1988;83:1140-4.
38. de Campos-Lobato LF, Geisler DP, da Luz MA, Stocchi L, Dietz D, Kalady MF. Neoadjuvant therapy for rectal cancer: the impact of longer interval between chemoradiation and surgery. J Gastrointest Surg 2011;15:444-50.